Sarepta surges as investors cheer expanded use of gene therapy
By Mariam Sunny and Bhanvi Satija June 21 – Sarepta Therapeutics shares surged as much as 40% to a more than three-year high on Friday as an expanded use approval cemented its dominant position in the gene therapy market for Duchenne muscular dystrophy . At current levels of $163.88, stock was set to add nearly … Read more